Bristol Myers Squibb - R&D News http://www.businesswire.com Business Wire - The global leader in news distribution en Copyright 2009, Business Wire. WebSupport@BusinessWire.com WebSupport@BusinessWire.com Mon, 23 Nov 2009 05:29:06 UT Mon, 23 Nov 2009 05:29:06 UT http://www.businesswire.com Business Wire http://www.businesswire.com Business Wire - The global leader in news distribution http://www.businesswire.com/images/bwlogo_small.gif 100 36 Bristol-Myers Squibb and Alder Biopharmaceuticals Enter Global Agreement on Rheumatoid Arthritis Biologic Tue, 10 Nov 2009 12:00:00 UT PRINCETON, N.J. & BOTHELL, Wash.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Alder Biopharmaceuticals, Inc., today announced a global agreement for the development and commercialization of ALD518, a novel biologic that has completed Phase IIa development for the treatment of rheumatoid arthritis. Under the terms of the collaboration agreement, Alder will grant to Bristol-Myers Squibb worldwide exclusive rights to develop and commercialize ALD518 for all potential indications ex http://www.businesswire.com/news/bms/20091110005283/en 20091110005283en Bristol-Myers Squibb and ZymoGenetics Present Final Phase 1b Results for PEG-Interferon Lambda in Hepatitis C Sat, 31 Oct 2009 21:30:00 UT PRINCETON, N.J. & SEATTLE--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and ZymoGenetics, Inc. (NASDAQ: ZGEN) today presented final results from a Phase 1b clinical trial of PEG-Interferon lambda administered with ribavirin in relapsed and treatment-naïve hepatitis C virus (HCV) patients. The poster included data on 56 patients in the study. Antiviral activity was observed at all dose levels tested. The results will be presented at the American Association for the Study of the http://www.businesswire.com/news/bms/20091031005013/en 20091031005013en Exelixis and Bristol-Myers Squibb Report New Phase 2 Data for XL184 in Patients With the Most Common and Aggressive Form of Brain Cancer Fri, 23 Oct 2009 22:40:00 UT SOUTH SAN FRANCISCO, Calif. & NEW YORK--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) and Bristol-Myers Squibb Company (NYSE:BMY) today reported updated phase 2 clinical data which show that XL184 demonstrated activity in patients with glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. The data from study XL184-201 were presented today during a poster session at the 2009 Joint Meeting of the Society for Neuro-Oncology and the AANS/CNS Section on Tumors. The study http://www.businesswire.com/news/bms/20091023005865/en 20091023005865en Study Finds That ONGLYZA™ (saxagliptin) When Added To Metformin Was Non-Inferior To JANUVIA (SITAGLIPTIN) When Added To Metformin In Reducing Hemoglobin (HbA1c) In Adults With Type 2 Diabetes Mellitus Mon, 5 Oct 2009 13:39:00 UT PRINCETON, N.J. and LONDON--(BUSINESS WIRE)--Results from an 18-week phase 3b study in adults with type 2 diabetes with inadequate glycemic control on metformin therapy alone found that the addition of treatment with ONGLYZA™ (saxagliptin) 5 mg per day achieved the primary objective of demonstrating non-inferiority compared to the addition of treatment with JANUVIA® (sitagliptin) 100 mg per day in reducing HbA1c from baseline. In this study, overall adverse events were reported at a s http://www.businesswire.com/news/bms/20091005005886/en 20091005005886en Bristol-Myers Squibb and ZymoGenetics to Present Final Phase Ib Data on PEG-Interferon Lambda at AASLD 2009 Thu, 1 Oct 2009 14:45:00 UT PRINCETON, N.J. & SEATTLE--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and ZymoGenetics, Inc. (NASDAQ:ZGEN) announced that final results from a Phase 1b clinical trial in patients with hepatitis C (HCV) treated with PEG-Interferon lambda, a new class of interferon, in combination with ribavirin will be presented at the American Association for the Study of Liver Diseases (AASLD) annual meeting October 30–November 3, 2009, in Boston. “Bristol-Myers Squibb is pleased to pa http://www.businesswire.com/news/bms/20091001005849/en 20091001005849en Data Presented from Two Phase 3 ERBITUX® Studies in First-Line Metastatic Colorectal Cancer Patients at Joint 15th European Cancer Organisation and 34th European Society for Medical Oncology Multidisciplinary Congress Wed, 23 Sep 2009 12:15:00 UT BERLIN--(BUSINESS WIRE)--According to a recent retrospective analysis of the pivotal Phase 3 CRYSTAL study, ERBITUX® (cetuximab), when added to FOLFIRI, was shown to increase median overall survival to 19.9 months in an intent-to-treat (ITT) population of first-line metastatic colorectal cancer (mCRC) patients compared to 18.6 months in those receiving FOLFIRI alone (hazard ratio [HR] 0.878; 95% CI 0.774 – 0.995; p=0.042). In a subset of mCRC patients with wild-type K-ras tumors, medi http://www.businesswire.com/news/bms/20090923005610/en 20090923005610en Bristol-Myers Squibb Announces Acceptance of Submission for Belatacept Biologic License Application Thu, 3 Sep 2009 21:03:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Food and Drug Administration (FDA) has accepted, for filing and review, the company’s submission of a biologic license application for belatacept, which is in ongoing phase III development for use in kidney transplantation. The Prescription Drug User Fee Act (PDUFA) goal date for the FDA is May 1, 2010. “Belatacept has the potential to address significant unmet medical needs of transplant http://www.businesswire.com/news/bms/20090903006091/en 20090903006091en U.S. Food and Drug Administration Approves ONGLYZA™ (saxagliptin) for the Treatment of Type 2 Diabetes Mellitus in Adults Fri, 31 Jul 2009 23:18:00 UT PRINCETON, N.J. & LONDON--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) approved ONGLYZA™ (saxagliptin), a http://www.businesswire.com/news/bms/20090803006030/en 20090803006030en U.S. Food and Drug Administration Approves ONGLYZA™ (saxagliptin) for the Treatment of Type 2 Diabetes Mellitus in Adults Fri, 31 Jul 2009 23:18:00 UT PRINCETON, N.J. & LONDON--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) approved ONGLYZA™ (saxagliptin), a http://www.businesswire.com/news/bms/20090731005799/en 20090731005799en ONGLYZA™ (Saxagliptin) Receives Positive Opinion in Europe for the Treatment of Type 2 Diabetes Thu, 25 Jun 2009 16:04:00 UT PARIS & LONDON--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced that their marketing authorization application for ONGLYZA™ (saxagliptin) received a positive http://www.businesswire.com/news/bms/20090625005756/en 20090625005756en Interim Analysis of Long-Term Data with ONGLYZA™ (saxagliptin) When Added to Metformin in People with Inadequately Controlled Type 2 Diabetes Presented at ADA Annual Scientific Sessions Sat, 6 Jun 2009 15:00:00 UT PRINCETON, N.J. & WILMINGTON, Del.--(BUSINESS WIRE)--Results from an interim analysis of a long-term Phase 3 study at 102 weeks with ONGLYZA™ (saxagliptin), an investigational, selective, reversible inhibitor of http://www.businesswire.com/news/bms/20090606005028/en 20090606005028en Dapagliflozin Study Demonstrated Improved Glycemic Control In Type 2 Diabetes Patients Treated With High Doses of Insulin and Common Oral Anti-Diabetic Medicines Sat, 6 Jun 2009 15:00:00 UT PRINCETON, N.J. & WILMINGTON, Del.--(BUSINESS WIRE)--Results from a 12-week study demonstrated that the investigational drug dapagliflozin, a novel, selective, sodium glucose co-transporter 2 (SGLT2) inhibitor, http://www.businesswire.com/news/bms/20090606005017/en 20090606005017en Exelixis and BMS Report Phase 2 Data to Be Presented at ASCO for XL184 in Patients with Previously Treated Glioblastoma Multiforme Sun, 31 May 2009 13:05:00 UT SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) and Bristol-Myers Squibb Company (NYSE:BMY) today reported encouraging data from an ongoing phase 2 trial of XL184 in http://www.businesswire.com/news/bms/20090531005045/en 20090531005045en Results from Three Phase 2 Studies Reported a Two-Year Survival Rate Ranging from 30 to 42 Percent in Metastatic Melanoma Patients Treated with Ipilimumab (10 mg/kg) Sun, 31 May 2009 12:00:00 UT PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Medarex, Inc. (NASDAQ: MEDX) today announced updated survival results from follow-up extensions of three Phase 2 ipilimumab studies of http://www.businesswire.com/news/bms/20090531005040/en 20090531005040en First Phase III Data on Innovative Compound for Solid Organ Transplantation To be Featured at American Transplant Congress Thu, 28 May 2009 18:00:00 UT NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that belatacept, an investigational co-stimulation blocker being studied for use in solid organ transplantation, will be the subject of http://www.businesswire.com/news/bms/20090528005109/en 20090528005109en Bristol-Myers Squibb and ZymoGenetics Present Positive 4-week Results of PEG-Interferon lambda with Ribavirin in Hepatitis C Fri, 24 Apr 2009 10:00:00 UT PRINCETON, N.J. & SEATTLE--(BUSINESS WIRE)--Bristol-Myers Squibb (NYSE: BMY) and ZymoGenetics, Inc. (NASDAQ: ZGEN) today reported that the administration of the investigational compound PEG-Interferon lambda in http://www.businesswire.com/news/bms/20090424005164/en 20090424005164en ONGLYZA™ (saxagliptin) Cardiovascular Profile Acceptable According to FDA Advisory Committee Wed, 1 Apr 2009 22:19:00 UT PRINCETON, N.J. & LONDON--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs http://www.businesswire.com/news/bms/20090401006562/en 20090401006562en Bristol-Myers Squibb Enters Global Collaboration with Nissan Chemical and Teijin Pharma on Novel Atrial Fibrillation Compound Thu, 5 Mar 2009 01:00:00 UT PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced a global collaboration with Nissan Chemical Industries, Ltd. and Teijin Pharma Limited for the development and http://www.businesswire.com/news/bms/20090304006180/en 20090304006180en Bristol-Myers Squibb and ZymoGenetics Enter Global Collaboration on Novel Hepatitis C Compound Mon, 12 Jan 2009 21:00:00 UT PRINCETON, N.J. & SEATTLE--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and ZymoGenetics, Inc. (Nasdaq: ZGEN) today announced a global collaboration for PEG-Interferon lambda, a novel type 3 interferon http://www.businesswire.com/news/bms/20090112006312/en 20090112006312en Howard Feldman Joins Bristol-Myers Squibb as Vice President and Therapeutic Area Head, Global Clinical Research, Neuroscience Thu, 8 Jan 2009 14:00:00 UT PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that Dr. Howard Feldman has joined the company's Research and Development organization as vice president and therapeutic area http://www.businesswire.com/news/bms/20090108005234/en 20090108005234en Bristol-Myers Squibb and Exelixis Enter Global Collaboration on Two Novel Cancer Programs Fri, 12 Dec 2008 10:54:00 UT PRINCETON, N.J. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Exelixis, Inc. (Nasdaq: EXEL) today announced a global collaboration covering two novel molecules for cancer http://www.businesswire.com/news/bms/20081212005212/en 20081212005212en Data Demonstrate ORENCIA(R) (abatacept) Improves Health-Related Quality of Life, Pain and Sleep Quality in Children With Juvenile Idiopathic Arthritis Tue, 28 Oct 2008 00:39:00 UT SAN FRANCISCO--(BUSINESS WIRE)-- http://www.businesswire.com/news/bms/20081027006546/en 20081027006546en Bristol-Myers Squibb and Pfizer Provide Update on Apixaban Clinical Development Program Tue, 26 Aug 2008 12:00:00 UT PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc (NYSE: PFE) provided an update on the apixaban clinical development program today. The companies announced that new http://www.businesswire.com/news/bms/20081211006335/en 20081211006335en Bristol-Myers Squibb and PDL BioPharma Enter Global Alliance to Develop Novel Treatment for Multiple Myeloma Tue, 19 Aug 2008 20:00:00 UT PRINCETON, N.J. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and http://www.businesswire.com/news/bms/20080819006170/en 20080819006170en Bristol-Myers Squibb and AstraZeneca Submit New Drug Application in the United States and Marketing Authorization Application in Europe for ONGLYZA(TM) (saxagliptin) for the Treatment of Type 2 Diabetes Wed, 23 Jul 2008 12:00:00 UT PRINCETON, N.J. & LONDON--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and http://www.businesswire.com/news/bms/20080723005568/en 20080723005568en Bristol-Myers Squibb to Acquire Kosan Biosciences Thu, 29 May 2008 13:22:00 UT PRINCETON, N.J. and HAYWARD, Calif.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Kosan Biosciences Inc. (NASDAQ: KOSN) announced today that the companies have signed a http://www.businesswire.com/news/bms/20080529005605/en 20080529005605en Bristol-Myers Squibb and KAI Pharmaceuticals Enter Global Alliance to Develop and Commercialize KAI-9803 for Cardiovascular Disease Tue, 13 May 2008 13:00:00 UT PRINCETON, N.J. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and KAI Pharmaceuticals, Inc., a privately held biotechnology company, today announced an http://www.businesswire.com/news/bms/20080513005869/en 20080513005869en Bristol-Myers Squibb to Acquire Adnexus Therapeutics Mon, 24 Sep 2007 12:00:00 UT PRINCETON, N.J. & WALTHAM, Mass.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Adnexus™ Therapeutics announced today the companies have signed a definitive agreement under which Bristol-Myers http://www.businesswire.com/news/bms/20081215005463/en 20081215005463en